Healthcare Wrap: FebriDx opens the US door as Atomo and Lumos slide, Cyclopharm rallies

• Atomo Diagnostics fell despite FebriDx’s US access widening, while Lumos also slid after landing a record US$1.3m order
• Cyclopharm led the gainers as Technegas added US contracts and pushed closer to guideline support
• Alterity and Enlitic jumped on FDA progress and new US hospital work, respectively
• Multiple trial read-outs and milestone dates are now set for June, August and November 2026